X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Lifestyle drugs: Potion for growth - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jun 3, 2003

    Lifestyle drugs: Potion for growth

    In the past few years, lifestyle drugs have emerged as the key growth drivers for the domestic pharma industry. Consequently, the past few years have seen companies increasingly focusing on this segment. In this context, let us understand the lifestyle drugs segment and itsí rising importance to the future growth of the companies.

    The various therapeutic segments have traditionally been the major growth drivers of Indian pharmaceutical industry. Among the various therapeutic segments, respiratory and anti-infectives were the key segments fuelling this growth. However, recently there has been a degrowth in the anti-infective segment resulting in a stagnant growth in the overall therapeutic segment. Increased competition and reduction in raw material costs has resulted in the anti-infectives pie shrinking by 4% in the past five years (1998-02). However, beating this trend of stagnancy, lifestyle drugs have become the fastest growing segment for the pharmaceutical companies. The following table shows the market growth rates for the month of March 2003.

    Therapeutic Segments Growth Snapshot (Mar - 03)
    Therapeutic Segment Market Growth Rate (%)
    Respiratory 5.6
    Anti-Infectives (0.20)
    Lifestyle Drugs:  
    Anti-Diabetics 20.3
    Cardio Vascular Segments 12.4
    CNS 13.4
    Source: Nicholas Piramal Ltd. Annual Report 2002-03

    From the table, it can be clearly seen that while the traditional therapeutic segments like respiratory and anti-infectives have registered a low or negative growth, lifestyle drugs for diabetes, cardio vascular segments and central nervous system (CNS) have seen double-digit growth rates.

    Lifestyle drugs are the medicines used to cure diseases that are linked to stress, urbanization and changing diet pattern and lifestyle of high-income level population. Major drugs in this segment are anti-diabetes drugs, cardiovascular system drugs, gentio-urinary and sex hormones drugs, CNS drugs, anti-depressants and psychiatry.

    The change to high-refined carbohydrate-based diets, coupled with relatively sedentary, low-activity lifestyle are leading to a significant growth in the risks of cardio-vascular, diabetic, oncological and other lifestyle related diseases, resulting in a rise in the demand for the drugs that cure these drugs. As the demand for lifestyle drugs is from the high-income group, doctors while recommending the same are more quality conscious than price and hence the demand for these drugs is not price sensitive. Consequently, the margins for this segment are also high. Rising demand and high margins have resulted in Indian companies concentrating more on lifestyle drugs.

    Many companies have now started tilting the balance in their product portfolio in favor of lifestyle drugs. For instance, in case of Nicholas Piramal Ltd. the share of lifestyle drugs in its portfolio increased from 24.5% in FY02 to 30.4% in FY03. In case of Sun Pharmaceuticals Ltd., the three segments of lifestyle drugs - Psychiatry and Neurology (31.5%), Cardiology (20.5%) and Diabetology (8.4%) together accounted for 60.5% of its total domestic prescription formulation sales in FY02. Ant-infectives, however, constituted for only 6.0% of revenues. In FY02, lifestyle drugs constituted 42% of the therapeutic segment for Wockhardt Ltd.

    Thus going forward, lifestyle drugs will be a vital constituent of the pharmaceutical sectorís growth story. Realizing this, companies are focusing more on lifestyle drugs and making aggressive new product launches in order to increase revenues and improve margins. However, more players in the market will result in increasing competition in the market and a squeeze in the margins in the medium term. Thus, only an innovative company that is able to introduce new products in the lifestyle segment will be able to extract full benefits from this segment.

     

     

    Equitymaster requests your view! Post a comment on "Lifestyle drugs: Potion for growth". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 17, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS